Ceftobiprole: Difference between revisions
From IDWiki
(Created page with "== Background == === Mechanism of Action === * Binds to and inhibits PBP-2a on MRSA * Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae ===...") |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | == |
+ | ==Background== |
| − | === |
+ | ===Mechanism of Action=== |
| − | * |
+ | *Binds to and inhibits PBP-2a on MRSA |
| − | * |
+ | *Binds to and inhibits PBP-2x on penicillin-resistant [[Streptococcus pneumoniae]] |
| − | === |
+ | ===Spectrum of Activity=== |
| − | * |
+ | *Active against [[MRSA]], ampicillin-susceptible [[Enterococcus]], and penicillin-resistant [[Streptococcus pneumoniae]], as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins |
| − | * |
+ | *Not active against [[Pseudomonas]], ESBL-producers, or AmpC-producers |
| + | === Pharmacokinetics and Pharmacodynamics === |
||
| ⚫ | |||
| + | * Crosses into CSF adequately |
||
| ⚫ | |||
| − | == |
+ | ==Dosing== |
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| ⚫ | |||
| + | |||
| + | * Required if CrCl <50 mL/min |
||
| + | |||
| + | ==Safety== |
||
| + | |||
| ⚫ | |||
| + | |||
| ⚫ | |||
[[Category:Cephalosporins]] |
[[Category:Cephalosporins]] |
||
Latest revision as of 10:05, 12 September 2020
Background
Mechanism of Action
- Binds to and inhibits PBP-2a on MRSA
- Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae
Spectrum of Activity
- Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses into CSF adequately
Dosing
- Ceftobiprole 500 mg IV q8h over 2 hours
Renal Dosing
- Required if CrCl <50 mL/min
Safety
Adverse Drug Reactions
- Nausea, diarrhea, neutropenia (4%), dysgeusia
